MEDIVIR AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.24 SEK | +6.23% |
|
+21.35% | +13.68% |
| Apr. 25 | Medivir Gets Two US FDA Designations for MIV-711 | MT |
| Mar. 21 | Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 21-MAR-2024. | CI |
Presentation Operator MessageOperator (Operator)Welcome to Medivir Q4 Report 2023. [Operator I...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Calendar
2024-04-29
- Q1 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.24
SEK
Average target price
20.55
SEK
Spread / Average Target
+534.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +13.68% | 33.11M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MVIR B Stock
- News Medivir AB
- Transcript : Medivir AB, Q4 2023 Earnings Call, Feb 15, 2024
